WELCOME TO iNANOD
NANO-TECHNOLOGY BASED CANCER DRUG DEVELOPMENT
WHAT WE DO
Current developments in nanomedicine research has inspired iNANOD co-founders to start an entrepreneurial journey utilizing nanotechnology to improve cancer treatment. iNANOD`s research is based on a nanotechnology-based platform, improving the efficacy and reducing side-effects of chemotherapeutic medications by optimizing drug delivery platform. This approach will ensure an optimal targeting and concentration of delivered drug to the diseased tissue. Our mission is to commercialize the research to benefit patients and society.
iNANOD AS is a newly established bio-tech company in Oslo, Norway. iNANOD utilizes nanotechnology to improve drug delivery within oncology, allowing for more targeted delivery of cancer medicines. iNANOD has a collaborative research strategy, applying the existing infrastructure surrounding Oslo. iNANOD is a member of the Oslo Cancer Cluster.
Ready to take the next step? You can become a contributor to our research program, and investment that will support the strategy to improve cancer therapy by utilizing the potential of nanotechnology in medicine. In case you are an investor or a philanthropist looking to support iNANOD, please contact us.
25 years of experience in drug development. Involved in more than 1000 projects involving clinical trials and regulatory affairs as a Clinical Research Organization executive chairman.
Professor in Department of Clinical Molecular Biology, Head (Epigenetics), Akershus University Hospital.
Co-founder and is a postdoctoral research scientist in Department of Clinical Molecular Biology, Akershus University Hospital.
Medical doctor with a PhD in the field of oncology. Various roles in the pharmaceutical and biotech industry including business development, clinical trial development, commercial operations and medical affairs.
Business angel. Business development and entrepreneurial experiences internationally over 28 years.
Entrepreneurial senior executive with extensive operational experience from the capital markets with multinational experience. Senior management experience from both start-ups as well as global, listed companies.
After 15 years of academic research in chemistry, turned entrepreneur for a mission.